A retrospective cohort study assessing the incidence of neutropenia and use of prophylactic granulocyte-colony stimulating factor (G-CSF) between nab-Paclitaxel plus gemicitabine and FOLFIRINOX in patients with metastatic pancreatic cancer.

Trial Profile

A retrospective cohort study assessing the incidence of neutropenia and use of prophylactic granulocyte-colony stimulating factor (G-CSF) between nab-Paclitaxel plus gemicitabine and FOLFIRINOX in patients with metastatic pancreatic cancer.

Completed
Phase of Trial: Phase IV

Latest Information Update: 31 May 2016

At a glance

  • Drugs Paclitaxel (Primary) ; Gemcitabine
  • Indications Pancreatic cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 31 May 2016 New trial record
    • 25 May 2016 Results presented at the 21st Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top